Final PBM Fee Disclosure Rule for Self-Insured Health Plans
Legal Alerts
11.19.26
Takeaways
-
-
- Two paths to coverage. The final rule covers qualifying self-insured group health plans under separate tests for single-employer plans and certain other plans, including multiemployer plans.
- Disclosures before contracting or renewal. Covered providers must disclose compensation reasonably in advance of a new contract, extension, or renewal. The Department of Labor considers 90 calendar days reasonable for extensions and renewals.
- Ongoing reporting. Covered providers must disclose compensation every six months, or quarterly if the plan requests it. Disclosures include rebates, spread compensation, and certain amounts recouped from pharmacies.
-
The Department of Labor (DOL) has finalized the transparency rule requiring pharmacy benefit managers (PBMs) and certain affiliated brokers and consultants to give plan fiduciaries more information about their fees and compensation. The rule is aimed at helping fiduciaries understand what their plans pay for PBM services, including compensation that may not be obvious from the service agreement.
Earlier this year, the DOL proposed requiring PBMs to give self-insured ERISA plans a clearer picture of that compensation. The rule applies to PBMs and their affiliated brokers and consultants who expect to receive more than $1,000 in compensation, including rebates, spread pricing, and claw-backs. Plan fiduciaries can use these disclosures to judge whether a PBM arrangement is reasonable, and they can audit the information at least once a year.
In the finalized rule, there are several items of note for plan sponsors.
-
-
-
Covered plans. Unlike the proposed rule, the final rule applies only to self-insured group health plans of a certain size. For single-employer plans, an employer averaging at least 100 employees during the preceding calendar year will be covered. For multiemployer and other multiple-employer plans, the coverage requirement is an average of 100 participants during the preceding plan year. Fully insured plans and plans sponsored by employers in the drug supply chain are excluded.
- More time before renewals. PBMs must provide initial disclosures reasonably before a contract is entered into, extended, or renewed. For extensions and renewals, providing them at least 90 days in advance is deemed reasonable.
- More insight into compensation. PBMs may use good-faith estimates based on the contract’s methodology and historical experience. The rule also addresses spread compensation and requires disclosure of certain retroactive pharmacy reimbursement adjustments.
- Stronger audit rights. Plans may audit the disclosures at least annually using an auditor of its choosing. Covered PBMs must make available relevant contracts with retail pharmacies, manufacturers, and rebate aggregators, as well as claims- and transaction-level data. Reasonable confidentiality agreements may limit how the information is used.
- Documentation matters. If a PBM fails to make a required disclosure, relief may be available to a fiduciary that was unaware of the failure and takes the required corrective steps. If the PBM does not cure the deficiency within 90 days, the fiduciary must notify the DOL. The fiduciary must also document why it decided to continue or terminate the arrangement.
-
-
The rule takes effect January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Until that applicability date, the DOL has announced a temporary enforcement policy for covered PBMs and responsible plan fiduciaries acting under a good-faith interpretation of the statutory requirements.
For plan sponsors, now is a good time to review PBM renewal dates, allow time to receive and assess disclosures, and make sure contracts support meaningful audit and termination rights. Please contact Dykema’s Employee Benefits team if you would like to discuss how the rule may affect your plan.